5 Best Small Cap Pharma Stocks to Buy Right Now

Page 1 of 5

In this article, we will be taking a look at the 5 Best Small Cap Pharma Stocks to Buy Right Now. If you wish to see the full list, visit 8 Best Small Cap Pharma Stocks to Buy Right Now.

5 Best Small Cap Pharma Stocks to Buy Right Now.

5. BioAge Labs, Inc. (NASDAQ:BIOA)

Number of Hedge Fund Holders: 24  

Market Capitalization: $850.83 million 

BioAge Labs, Inc. (NASDAQ:BIOA) is one of the best small cap pharma stocks to buy right now.

TheFly reported on May 13 that BIOA received newly initiated coverage with a Buy rating and a $40 price target by BITG. The company is described as a clinical-stage biopharmaceutical firm targeting diseases associated with human aging through analysis of large human datasets to identify biological markers that influence long-term health outcomes. The outlook highlights a roughly four-year cash runway and upcoming clinical catalysts, including BGE-102 expected in the second half of 2026 and BGE-105 anticipated in mid-2027. The lead cardiovascular risk program is viewed as biologically de-risked based on evidence linking reductions in systemic inflammation with improved clinical outcomes, supporting the firm’s positive stance on the development pipeline.

Additionally, on May 8,  BioAge Labs, Inc. (NASDAQ:BIOA) reported first-quarter 2026 financial results for the period ended March 31, 2026, alongside a business update. Collaboration revenue increased to $2.8 million from $1.5 million a year earlier, driven by higher activity under its Novartis agreement.

Research and development expenses rose to $20.4 million, reflecting increased spending on the BGE-102 program, including late-stage Phase 1 completion work, preparation for upcoming Phase 2 cardiovascular risk studies, and expansion into additional proof-of-concept trials. Additional R&D costs were driven by other pipeline programs and manufacturing efforts. General and administrative expenses increased to $7.7 million due to higher personnel costs and legal expenses. Net loss widened to $22.3 million, while cash reserves stood at approximately $384.9 million, supporting operations through 2029.

BioAge Labs, Inc. (NASDAQ:BIOA) is a clinical-stage biopharmaceutical company developing therapies for metabolic and age-related diseases by targeting the biological drivers of aging.

Page 1 of 5
1281292 - 11759070 - 1